• Halozyme Therapeutics average return on equity for 2024 was 163.94, a 3.08% decline from 2023.
• Halozyme Therapeutics average return on equity for 2023 was 169.15, a 24.38% decline from 2022.
• Halozyme Therapeutics average return on equity for 2022 was 135.99, a 37.27% increase from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.